Monozygotic transplantation: concerns and opportunities

Area of Science:

• Nephrology
• Immunology
• Transplantation

Background:

• End-stage renal disease (ESRD) management often requires lifelong immunosuppression post-transplantation.
• Focal segmental glomerulosclerosis (FSGS) is a leading cause of ESRD, with a risk of recurrence in allograft recipients.
• Monozgotic (identical) twin transplantation offers a unique model to study the necessity of immunosuppression.

Observation:

• A case study of a 24-year-old female with FSGS who received a kidney transplant from her identical twin and successfully discontinued immunosuppression.
• Analysis of the Organ Procurement and Transplant Network (OPTN) database (1987-2006) identified 194 probable HLA-identical twin transplantations.
• Evaluation of immunosuppressive drug use revealed that 71% of recipients were on medication at discharge, decreasing to 34% at 1 year.

Findings:

• A significant proportion of recipients (66%) remained on calcineurin inhibitors one year post-transplant.
• Patients not maintained on immunosuppression demonstrated superior renal function compared to those who were.
• Monozgotic transplantation appears to confer an immunologic advantage, potentially enabling immunosuppression withdrawal.

Implications:

• Elimination of immunosuppression in select monozygotic twin transplant recipients may improve long-term outcomes.
• This approach highlights the potential for reduced treatment burden and side effects.
• Ongoing monitoring is essential to manage risks, including the potential for recurrent FSGS in the transplanted kidney.